Broadfin Capital’s Agile Therapeutics AGRX Stock Holding History

Broadfin Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-179	Closed	-$964K	–	58
2017 Q4	$964K	Buy	+179	New	+$1.67M	0.16%	41

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Broadfin Capital's AGRX Position: Q1 2018 in Review

Broadfin Capital sold out of Agile Therapeutics (AGRX) in Q1 2018, closing a stake of 179 shares — an estimated $964K sold.

Broadfin Capital first reported a position in AGRX in Q4 2017 and held it in 1 quarter. The position peaked at $964K in Q4 2017. 46 funds tracked by Wall St. Rank hold AGRX as of Q1 2018.

Broadfin Capital reported no remaining Agile Therapeutics position as of Q1 2018 after selling out during the quarter.
Broadfin Capital sold 179 Agile Therapeutics shares in Q1 2018, an estimated $964K.
Broadfin Capital first reported a position in Agile Therapeutics in Q4 2017 and held it in 1 quarter.
Broadfin Capital's Agile Therapeutics position peaked at $964K in Q4 2017.
46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2018.

Based on Broadfin Capital's 13F filing for Q1 2018, filed 14 May 2018.